ESMO 2025 - Complete program listing

Daily recaps and interviews from the ESMO 2025

Drs. Jamil Asselah, Rami Younan, and Kim Ma review major Day 1 updates from ESMO 2025 in early breast cancer—monarchE overall survival, 5-year NATALEE, and POSITIVE trial results—while previewing upcoming data in neoadjuvant, post-neoadjuvant, and metastatic settings to be discussed in the days ahead.Drs. Kim Ma and Nathalie LeVasseur review and discuss adjuvant CDK4/6 inhibitor data presented on Day 1 of ESMO 2025, highlighting key updates from monarchE and NATALEE trials and how these findings may influence patient care in early breast cancer.

Dr. Sara Hurvitz reviews findings from VIKTORIA-1, a phase 3 international open-label randomized trial, highlighting early promising trends that may influence treatment strategies and improve patient outcomes in breast cancer care.

Dr. Karen Gelmon shares her reflections from Day 2 at ESMO 2025, highlighting the POSITIVE trial and its impact on pregnancy outcomes for women wishing to conceive, along with her insights and guidance for both patients and clinicians.

Drs. Asselah, Younan, and Ma share Day 2 highlights from ESMO 2025, noting encouraging results across breast cancer studies, with special mentions to DESTINY-Breast11, DESTINY-Breast05, ASCENT-03, and TROPION-Breast02 — and more exciting updates to come tomorrow.

Dr. Sara Soldera discusses the monarchE study results presented at ESMO 2025, highlighting the overall survival benefit in the adjuvant setting, how these findings reinforce current practice, and what they mean for patients with early breast cancer.

Dr. Kevin Kalinsky shares his perspective on the most significant breast cancer data from ESMO 2025, including updates from NATALEE, monarchE, DESTINY-Breast05 & 11, ASCENT-03, and TROPION-Breast02—highlighting key findings shaping treatment practice.

Dr. Mita Manna shares her review of the latest breast cancer data from ESMO 2025, covering all three major subtypes. As Chair of the REAL Alliance, she also announces upcoming consensus recommendations and Canadian practice guidance to be published soon.

Dr. Christos Sotiriou shares key insights from his ESMO 2025 presentation on exceptional responders in metastatic cancer, exploring molecular and clinical factors that help identify patients who achieve extraordinary outcomes with targeted therapies.

Prof. Rebecca Dent presents the much-anticipated primary results from the randomized phase III TROPION-Breast02 trial at ESMO 2025, sharing key outcomes that could redefine treatment strategies in advanced breast cancer.